Collaborative Drug Discovery Through Comprehensive Multi-discipline Scientific Experience
The pharmaceutical industry is undergoing major transformations to respond to innovation challenges it is facing. R&D productivity is under pressure as regulatory bodies and paying institutions are demanding more and more evidences that a new drug compound addresses an unmet medical need. Among those evidences, in silico predictions and simulation results are rising as a new important piece of the regulatory submission file. This pressure combined with a new external economic environment and the growing market share of generic manufacturers are all taking a serious toll on the short- and long-term performance of pharmaceutical firms.
Dassault Systèmes, in collaboration with industry leaders of the BioIntelligence Consortium, have developed a comprehensive suite of BioPLM solutions to address these challenges and improve the efficiency and effectiveness of the drug discovery and development process. Through global scientific collaboration, scientific content federation and semantic search, and virtual modeling and predictive simulations, pharmaceutical researchers and their global ecosystem can quickly and more efficiently create new drugs and improve the success rate of delivering new, better targeted therapeutic solutions.
Leverage a global knowledge compendium through an intuitive navigation experience and unique scientific referential integrating heterogeneous biological data bases. Based on the 3DEXPERIENCE platform, the collaborative environment enables multisite research project management and increases external ecosystem collaboration.
Predict drug efficacy by quantitatively simulating the evolution of biological endpoints based on systems biology to understand and leverage your experimental data. Model the physiologically based pharmacokinetics of your leading drug and help you design the clinical trial that will reveal the best efficacy.
A comprehensive solution to predict drug safety, including immunogenicity risk of biomolecules, long term toxicity based on early phase experimental data, and toxicity of candidate drugs based on chemical and biological discovery data.
The power of the digital world can help to fundamentally transform the industry's current practices
Christophe Thurieau, Ipsen Senior Vice President of Scientific Affairs
and President of Ipsen Innovation